TY - JOUR AU - Gentilini, Fabiana AU - Levi, Anna AU - Federico, Vincenzo AU - Russo, Eleonora AU - Foà, Robin AU - Petrucci, Maria Teresa PY - 2012/05/07 Y2 - 2024/03/29 TI - Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis JF - Mediterranean Journal of Hematology and Infectious Diseases JA - Mediterr J Hematol Infect Dis VL - 4 IS - 1 SE - Case Reports DO - 10.4084/mjhid.2012.035 UR - https://www.mjhid.org/mjhid/article/view/2012.035 SP - e2012035 AB - <p><strong>Introduction: </strong>Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow micro-environment. Intravenous Bortezomib (1.3 mg/m<sup>2</sup> administered on days 1,4,8 and 11 of a 21 day cycle), with or without dexamethasone, is effective and well tolerated in patients with relapsed/refractory multiple myeloma (MM).</p><p><strong>Methods:  </strong>We treated a MM patient with<strong> </strong>Cystic Fibrosis with Bortezomib alone to avoid the use of corticosteroid and consequently the risk of lung infection reactivations, first of all due to the patient <em>Pseudomonas aeruginosa</em> colonization. Bortezomib was administrated at 1.3 mg/m<sup>2</sup> on days 1,4,8 and 11 with a 10 day rest period  and four 21-day cycles were administered. We evaluate the treatment response and toxicity.</p><p><strong>Results: </strong>After four cycles of therapy the patient achieved a<strong>  </strong>very good partial response (VGPR) according to the IMWG response criteria, without clinically significant side effects.</p><p><strong>Conclusions:</strong> Bortezomib can be successfully utilized for the management of this difficult disease situation</p> ER -